ストックスクリーナーアプリを入手
3.36
0.30%
0.010
アフターアワーズ：
3.36
前日終値:
$3.35
開ける：
$3.32
24時間の取引高:
90,794
Relative Volume:
0.49
時価総額：
$283.66M
収益：
$351.37M
当期純損益:
$-135.96M
株価収益率:
-2.625
EPS:
-1.28
ネットキャッシュフロー:
$-85.40M
1週間 パフォーマンス:
-0.88%
1か月 パフォーマンス:
-2.89%
6か月 パフォーマンス:
-15.15%
1年 パフォーマンス:
+2.75%
1日の値動き範囲:
$3.285
$3.365
1週間の範囲:
$3.22
$3.45
52週間の値動き範囲:
$2.765
$4.60
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-08-10 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-01-06 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-10-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | 開始されました | Evercore ISI | Outperform |
| 2020-11-24 | 開始されました | JP Morgan | Overweight |
| 2020-11-24 | 開始されました | Morgan Stanley | Overweight |
| 2020-11-24 | 開始されました | William Blair | Outperform |
すべてを表示
Atea Pharmaceuticals Inc (AVIR) 最新ニュース
AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Thursday - MarketBeat
Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 - The Manila Times
Atea Pharmaceuticals to Present New Data Supporting the - GlobeNewswire
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024 - StockTitan
SG Americas Securities LLC Increases Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Morgan Stanley Upgrades Atea Pharmaceuticals (AVIR) - MSN
Atea Pharmaceuticals Leads The Charge In US Penny Stocks Spotlight - Simply Wall St
ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock? - Benzinga
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance
Dimensional Fund Advisors LP Buys 211,428 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
182,326 Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Purchased by Marshall Wace LLP - MarketBeat
Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Almitas Capital LLC Invests $4.27 Million in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Metrics That Matter About Atea Pharmaceuticals Inc (NASDAQ: AVIR) - Stocks Register
Jean-Pierre Sommadossi Sells 33,941 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Stock - MarketBeat
Atea Pharmaceuticals CEO sells over $234k in company stock - Investing.com India
Atea Pharmaceuticals CEO sells over $234k in company stock By Investing.com - Investing.com UK
Q3 2024 EPS Estimates for Atea Pharmaceuticals, Inc. Lifted by Analyst (NASDAQ:AVIR) - MarketBeat
Data from Merck, Daiichi could support first approval for HER3 ADC - BioCentury
Atea Pharmaceuticals (NASDAQ:AVIR) & SELLAS Life Sciences Group (NASDAQ:SLS) Critical Analysis - Defense World
Short Interest in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Rises By 13.7% - MarketBeat
Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus - AOL
AVIR’s price-to-cash ratio: Is it a good investment at the moment? - US Post News
Atea Pharmaceuticals Shares Fall on Covid-19 Treatment Trial Result - MarketWatch
Atea stock drops as COVID-19 therapy fails in late-stage trial - MSN
Atea stock falls after setback to COVID-19 drug (NASDAQ:AVIR) - Seeking Alpha
Atea Pharmaceuticals reports Phase 3 trial miss for COVID-19 drug - Investing.com
Atea Pharmaceuticals Trial of Covid-19 Treatment Bemnifosbuvir Fails to Meet Primary Endpoint - MarketWatch
Atea Pharmaceuticals Provides Update on Global Phase 3 - GlobeNewswire
Atea Pharmaceuticals Provides Update on Global Phase 3 Rise-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19 - Marketscreener.com
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Acadian Asset Management LLC - Defense World
Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19 - Yahoo Finance
New Data on Bemnifosbuvir's Progress in COVID-19 and HCV Trials - Contagionlive.com
Atea Pharmaceuticals advances antiviral drug study - Investing.com
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by SG Americas Securities LLC - Defense World
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway - ForexTV.com
Atea Pharmaceuticals Announces Publication of Additional - GlobeNewswire
California State Teachers Retirement System Cuts Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Price T Rowe Associates Inc. MD Has $272,000 Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea rises after Morgan Stanley upgrade - MSN
Atea stck rises after Morgan Stanley upgrade (NASDAQ:AVIR) - Seeking Alpha
Atea Pharmaceuticals (NASDAQ:AVIR) Upgraded to "Equal Weight" at Morgan Stanley - MarketBeat
Atea Pharmaceuticals (NASDAQ:AVIR) Upgraded by Morgan Stanley to Equal Weight - Defense World
All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy - MSN
Q3 2024 Earnings Estimate for Atea Pharmaceuticals, Inc. Issued By William Blair (NASDAQ:AVIR) - MarketBeat
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Stock Holdings Increased by Vanguard Group Inc. - Defense World
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2024 Earnings Call Transcript - Insider Monkey
21,472 Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Acquired by Tidal Investments LLC - Defense World
Atea Pharmaceuticals Inc (AVIR) 財務データ
収益
当期純利益
現金流量
EPS
Atea Pharmaceuticals Inc (AVIR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sommadossi Jean-Pierre | President, CEO, and Chairman |
Sep 18 '24 |
Sale |
4.03 |
22,187 |
89,469 |
5,867,866 |
| Sommadossi Jean-Pierre | President, CEO, and Chairman |
Sep 19 '24 |
Sale |
4.00 |
1,841 |
7,367 |
5,866,025 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):